Navigation Links
Cancer Centers of North Carolina Offers HDR Brachytherapy for Treatment of Cancerous Tumors
Date:8/5/2009

RALEIGH, N.C., Aug. 5 /PRNewswire/ -- Cancer Centers of North Carolina, an affiliate of US Oncology, Inc., continues to offer cutting-edge treatment options to its patients through the addition of High Dose Rate (HDR) brachytherapy. This latest advance in brachytherapy allows physicians to deliver precise radiation treatment to a patient's cancerous tumor and is rapidly becoming the treatment of choice for certain types of cancer.

With HDR brachytherapy, radiation is delivered directly to the cancer target through the use of catheters, needles or applicators inserted into a body cavity or directly into the tumor. A computer-controlled delivery system is used to optimize the dose distribution to the target. As a result of this precise delivery, the surrounding healthy tissue and critical organs are preferentially spared from high doses of radiation and side effects may be reduced.

Unlike low dose rate brachytherapy treatment, HDR therapy can be delivered on an outpatient basis at Cancer Centers of North Carolina's office, which incorporates all patient needs in one central location. In addition, treatment times for HDR brachytherapy are typically 10-15 minutes in duration instead of several days that are required for low dose rate brachytherapy. Cancer Centers of North Carolina is currently administering HDR primarily on breast and gynecologic cancers.

The HDR brachytherapy program at Cancer Centers of North Carolina is directed by its board-certified radiation oncologists, Dr. John Reilly and Dr. Kolby Sidhu. "HDR brachytherapy is a very effective addition to our fight against cancer. This technique delivers a high dose of radiation directly to the area of disease," according to Dr. Reilly. Dr. Sidhu adds, "Cancer patients
'/>"/>

SOURCE US Oncology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Novel Technology Breaks Through Cancer Pain
8. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
9. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)...  Spring Bank Pharmaceuticals, Inc., a biopharmaceutical company developing ... announced that it has initiated dosing in a Phase ... oral therapy for the treatment of HCV infection. This study ... designed to assess both the safety and antiviral efficacy ... for the treatment of chronic HCV infections and is ...
(Date:5/23/2013)... FREDERICK, Md. , May 23, 2013  BioElectronics ... safe consumer medical devices, comments on the FDA panel ... Public Advisory Panel Reclassification – Pulsed Shortwave Therapy Meeting ... Gaithersburg, MD , USA.  The focus of the ... instructed the panel to focus solely on the application ...
(Date:5/23/2013)... DIEGO , May 23, 2013 ... today announced the appointment of David ... Mr. Ramsay was most recently Vice President, Corporate ... http://photos.prnewswire.com/prnh/20100302/LA63139LOGO )     "With his established financial ... experience gained by working in our commercial group ...
Breaking Medicine Technology:Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 2Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 3BioElectronics and Pulsed Shortwave Therapy Make Progress 2Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer 2
... SEATTLE, May 2, 2011 CMC Biologics, a ... Copenhagen, Denmark and Seattle, Washington USA, announced today ... at its Chief Executive Officer. CMC Biologics, a ... world class, fully integrated, biopharmaceutical process development and ...
... SAN DIEGO, May 2, 2011 Volcano Corporation (NASDAQ: ... of precision intravascular diagnosis and therapy guidance tools designed ... disease, said today that it will be participating in ... May 10. The presentation by John Dahldorf, ...
Cached Medicine Technology:CMC Biologics Announces Appointment of New CEO 2
(Date:5/23/2013)... DC (PRWEB) May 23, 2013 “Talk. ... (PSA) campaign that empowers parents to talk to children ... of underage drinking, was launched today by the Substance ... The kickoff occurred in conjunction with SAMHSA’s 2013 National ... of, and action around, substance abuse and mental health ...
(Date:5/23/2013)... Live Lead Pros , with its ... business lead solution via its smart solution for ... features Free Web Based Account Management, Database Usage, ... "Automatic Transfer Retry". The company has recently announced ... system. , Its Free Database Usage offers their ...
(Date:5/23/2013)... anti-cancer drug about to be tested in a clinical ... possible treatment for Alzheimer,s disease has failed to work ... Alzheimer,s patients, according to results of a study by ... professor of neuroscience affiliated with the Evelyn F. and ... Florida, emphasized the importance of verifying promising research results ...
(Date:5/23/2013)... characterized as "triple negative" carries a poor prognosis, with ... kill the cancer cells the way it,s supposed to. ... cells don,t respond to chemotherapy, and identifies a mechanism ... Dr. Shawn Li, PhD, and his team at Western,s ... protein called Numb functions to promote the death of ...
(Date:5/23/2013)... New York, New York (PRWEB) May 23, 2013 ... products manufactured by C.R. Bard, Inc., continue to move ... District Court, Southern District of West Virginia, Bernstein Liebhard ... 17th, the Court denied a request by C.R. Bard ... claimed would reveal trade secrets and other confidential, proprietary ...
Breaking Medicine News(10 mins):Health News:New Campaign to Help Parents Talk to Younger Children About the Dangers of Underage Drinking 2Health News:Live Lead Pros Announces The Benefits of Comprehensive Campaign Delivery and Management System 2Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 2Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 3Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 2Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 3
... taken by European governments and healthcare authorities ... at improving efficiency levels and reducing expenditures. ... is proving to be a major challenge.(Logo: ... from governments across Europe to install infection ...
... Programs Supported by a Grant from Otsuka America ... quality of care and increasing awareness of and ... communities are all values held by the 2009 ... for Advancing Minority Mental Health.The awards, presented by ...
... 5 Nutrition 21, Inc. (Nasdaq: NXXI ), ... manage blood sugar levels, improve cardiovascular health, enhance memory and ... to the opening of the market - on Tuesday, May ... ended March 31, 2009. The Company has scheduled a conference ...
... Market for Women,s Health Devices Worth $2.1 Billion in ... research reports by iData Research ( www.idataresearch.net ) - ... firm - the U.S. market for female sterilization devices ... market, transcervical sterilization devices, which grew over 54% in ...
... $19.7 Million -- Same-Store Sales Increased 1.1% -- Net Cash ... Loss Improved 18.0% to $17.2 Million - , NEW YORK, ... results for the first quarter ended March 28, 2009. Key ... Adjusted FIFO EBITDA increased 7.8% to $19.7 ...
... coli, K. pneumoniae and P. aeruginosa Directly from ... Hours Sooner Than Conventional Methods to Help Clinicians ... Gram-Negative Bloodstream InfectionsWOBURN, Mass., and VEDBAEK, Denmark, May ... 510(k) clearance for EK/ P. aeruginosa PNA ...
Cached Medicine News:Health News:Frost & Sullivan: Rising Public Awareness Promoting Acceptance of Infection Surveillance Systems Across Europe 2Health News:Frost & Sullivan: Rising Public Awareness Promoting Acceptance of Infection Surveillance Systems Across Europe 3Health News:American Psychiatric Foundation Names 2009 Recipients of Awards for Advancing Minority Mental Health 2Health News:American Psychiatric Foundation Names 2009 Recipients of Awards for Advancing Minority Mental Health 3Health News:American Psychiatric Foundation Names 2009 Recipients of Awards for Advancing Minority Mental Health 4Health News:Nutrition 21 to Report Third Quarter Fiscal Year 2009 Financial Results on Tuesday, May 12, 2009 2Health News:U.S. Market for Female Sterilization Devices to Grow 36% in 2009 2Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 2Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 3Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 4Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 5Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 6Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 7Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 8Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 9Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 10Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 11Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 12Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 13Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 14Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 15Health News:AdvanDx Receives FDA 510(k) Clearance for EK/P. aeruginosa PNA FISH(R) 2Health News:AdvanDx Receives FDA 510(k) Clearance for EK/P. aeruginosa PNA FISH(R) 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: